Company / Financials
SAB Biotherapeutics, Inc. Financials
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$1.3M
FY2025 · -40.9% YoY
Net Income
-$34.1M
FY2025 · +19.2% YoY
Profit Margin
-2579.0%
FY2025 · net income / revenue
ROE
-131.3%
FY2025 · return on equity
Total Assets
$172.8M
FY2025
Total Debt
-
FY2025
Equity
$26.0M
FY2025
ROA
-19.7%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$1.3M-40.9% YoYNet Income HistoryProfit after all expenses and taxes-$34.1M+19.2% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$42.9M-12.7% YoYSG&A Expense HistorySelling, general, and administrative expenses$14.0M-41.3% YoYR&D Expense HistoryResearch and development spending$30.3M+83.2% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$3.68+51.8% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$3.68+51.8% YoYShares Outstanding HistoryWeighted average diluted shares outstanding9.3M+0.7% YoY